Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
Click here to read more about us!InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
Click here to read more about us!InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a
SE-171 77 Stockholm, Sweden
